These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25207247)

  • 1. Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer.
    Lee HY; Kim JI; Cho SH; Ko TY; Kim HS; Park SD; Cho SR; Chang HK; Hwang GJ; Jung SB
    Korean J Thorac Cardiovasc Surg; 2014 Aug; 47(4):378-83. PubMed ID: 25207247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
    Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
    PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
    Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
    Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma.
    Chen K; Huang W; Huang B; Wei Y; Li B; Ge Y; Qin Y
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):160-5. PubMed ID: 23237599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.
    Kosaka-Suzuki N; Suzuki T; Pugacheva EM; Vostrov AA; Morse HC; Loukinov D; Lobanenkov V
    J Biol Chem; 2011 Aug; 286(31):27378-88. PubMed ID: 21659515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.
    Akhtar MS; Akhter N; Talat A; Alharbi RA; Sindi AAA; Klufah F; Alyahyawi HE; Alruwetei A; Ahmad A; Zamzami MA; Deo S; Husain SA; Badi OA; Khan MJ
    Oncotarget; 2023 May; 14():528-541. PubMed ID: 37235839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.
    Velázquez-Hernández N; Reyes-Romero MA; Barragán-Hernández M; Guerrero-Romero F; Rodríguez-Moran M; Aguilar-Durán M; Lazalde Medina B
    Genet Mol Res; 2015 Jun; 14(2):6094-100. PubMed ID: 26125810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
    Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
    Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
    Zhang Y; Fang M; Song Y; Ren J; Fang J; Wang X
    Sci Rep; 2017 Jan; 7():40786. PubMed ID: 28098226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brother of regulator of imprinted sites inhibits cisplatin-induced DNA damage in non-small cell lung cancer.
    Zhang Y; Song Y; Li C; Ren J; Fang M; Fang J; Wang X
    Oncol Lett; 2020 Nov; 20(5):251. PubMed ID: 32994814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent activation of putative oncogene SBSN by BORIS.
    Gaykalova D; Vatapalli R; Glazer CA; Bhan S; Shao C; Sidransky D; Ha PK; Califano JA
    PLoS One; 2012; 7(7):e40389. PubMed ID: 22792300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BORIS in human cancers -- a review.
    Martin-Kleiner I
    Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions.
    El-Sharkawy NM; Radwan WM; Essa ES; Kandeel EZ; Abd El-Fattah EK; Kandil SH; Kamel AM
    Cytometry B Clin Cytom; 2017 Sep; 92(5):355-360. PubMed ID: 27219508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
    Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
    Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
    Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
    Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
    Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
    Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.
    Okabayashi K; Fujita T; Miyazaki J; Okada T; Iwata T; Hirao N; Noji S; Tsukamoto N; Goshima N; Hasegawa H; Takeuchi H; Ueda M; Kitagawa Y; Kawakami Y
    Cancer Sci; 2012 Sep; 103(9):1617-24. PubMed ID: 22676270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas - a pilot study.
    Novak Kujundžić R; Grbeša I; Ivkić M; Krušlin B; Konjevoda P; Gall Trošelj K
    Pathol Oncol Res; 2014 Jul; 20(3):687-95. PubMed ID: 24563233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.
    Janssen SM; Moscona R; Elchebly M; Papadakis AI; Redpath M; Wang H; Rubin E; van Kempen LC; Spatz A
    Cell Death Discov; 2020; 6():1. PubMed ID: 32123577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.